- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03774797
Feasibility of Immediate Postpartum Long-acting Reversible Contraception Implementation
11 februari 2021 bijgewerkt door: Michelle H. Moniz, University of Michigan
Immediate Postpartum LARC Implementation: Pilot Study at Michigan Medicine
The objective of this study is to test and disseminate tools that drive successful immediate postpartum Long-Acting Reversible Contraception (LARC) implementation.
The long-term goal is to reduce unintended pregnancy soon after childbirth by increasing access to immediate postpartum LARC for women who desire it.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Based on previous work, the investigators have generated a toolkit to guide the integration of immediate postpartum LARC services into widespread clinical practice.
In the proposed work, this toolkit will be used to initiate immediate postpartum LARC services in a single site with low baseline immediate postpartum LARC uptake (Michigan Medicine).
The investigators will conduct a feasibility study using mixed methods to assess acceptability and appropriateness of toolkit items; patient experience of care; immediate postpartum LARC utilization rate; and prenatal contraceptive counseling rate.
Studietype
Observationeel
Inschrijving (Werkelijk)
592
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Michigan Medicine
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
Study population includes women receiving prenatal care and maternity providers working at the study site.
The patient populations includes approximately 5000 women annually.
The provider population includes approximately 400 maternity providers.
Beschrijving
Inclusion Criteria:
- Female (patients)
- Pregnant (patients)
- Receiving obstetrical care at Michigan Medicine (patients)
- L&D provider at Michigan Medicine (providers)
Exclusion Criteria:
- non-English speaking
- unable to provide informed consent
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Pre-Implementation Patients
Enrolled patients will take online surveys following a prenatal or a postpartum visit.
|
|
|
Post-Implementation Patients
All enrolled patients will take online surveys following a prenatal or a postpartum visit.
A subset will be interviewed after the postpartum survey.
|
Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
|
|
Post-Implementation Providers
All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
|
Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Patient experience of care
Tijdsspanne: Surveys will be collected from pregnant or postpartum women, during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
Patient online surveys about their experience of care during prenatal visits, hospital stay, or postpartum office visit
|
Surveys will be collected from pregnant or postpartum women, during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
|
Acceptability of care process - patients
Tijdsspanne: Surveys will be collected from pregnant or postpartum women, during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
Online survey assessing experience of care, acceptability and appropriateness of implementation tools
|
Surveys will be collected from pregnant or postpartum women, during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
|
Appropriateness of care process - patients
Tijdsspanne: Surveys will be collected from pregnant or postpartum women, during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
Online survey assessing experience of care, acceptability and appropriateness of implementation tools
|
Surveys will be collected from pregnant or postpartum women, during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
|
Acceptability of implementation process - study site maternity care providers
Tijdsspanne: Surveys will be collected during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
Online survey assessing overall experience of care delivery, acceptability and appropriateness of implementation tools
|
Surveys will be collected during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
|
Appropriateness of implementation process - study site maternity care providers
Tijdsspanne: Surveys will be collected during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
Online survey assessing overall experience of care delivery, acceptability and appropriateness of implementation tools
|
Surveys will be collected during the 6-12 months after implementation of a new protocol for peripartum contraceptive care
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Acceptability of implementation toolkit items - patients
Tijdsspanne: Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
30-minute follow-up in-person interview of subgroup of patients who completed surveys
|
Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
|
Appropriateness of implementation toolkit items - patients
Tijdsspanne: Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
30-minute follow-up in-person interview of subgroup of patients who completed surveys
|
Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
|
Acceptability of implementation toolkit items - providers
Tijdsspanne: Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
30-minute follow-up in-person interview of subgroup of providers who completed survey
|
Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
|
Appropriateness of implementation toolkit items - providers
Tijdsspanne: Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
30-minute follow-up in-person interview of subgroup of providers who completed survey
|
Interviews will take place after the survey is completed, during the 6-18 months after implementation of a new protocol for peripartum contraceptive care
|
|
Perinatal contraceptive counseling rate
Tijdsspanne: Measured monthly, up to 24 months after toolkit implementation
|
Proportion of delivered patients with documentation of prenatal counseling about postpartum contraception
|
Measured monthly, up to 24 months after toolkit implementation
|
|
Immediate postpartum LARC provision rate
Tijdsspanne: Measured monthly, up to 24 months after toolkit implementation
|
Proportion of delivered patients with documentation of preference for immediate postpartum LARC who receive a LARC device
|
Measured monthly, up to 24 months after toolkit implementation
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Michelle H. Moniz, MD, MSc, University of Michigan
- Hoofdonderzoeker: Vanessa K. Dalton, MD, MPH, University of Michigan
- Hoofdonderzoeker: Michelle Heisler, MD, MPH, University of Michigan
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 september 2018
Primaire voltooiing (Werkelijk)
16 augustus 2020
Studie voltooiing (Werkelijk)
16 augustus 2020
Studieregistratiedata
Eerst ingediend
20 november 2018
Eerst ingediend dat voldeed aan de QC-criteria
11 december 2018
Eerst geplaatst (Werkelijk)
13 december 2018
Updates van studierecords
Laatste update geplaatst (Werkelijk)
12 februari 2021
Laatste update ingediend die voldeed aan QC-criteria
11 februari 2021
Laatst geverifieerd
1 februari 2021
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- HUM00126810
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .